This protocol addresses a defined low-risk subgroup of essential thrombocythemia: patients aged 60 years or younger with no prior thrombosis who carry a JAK2 mutation. Risk stratification in ET separates this low-risk group from the very-low-risk category precisely on the basis of JAK2 mutation status.
The preceding treatment line used low-dose aspirin (once- or twice-daily). This protocol applies when that regimen did not achieve its intended goal: alleviation of vasomotor (microvascular) disturbances. Persistent vasomotor symptoms despite aspirin is the clinical trigger for escalation to this next-line approach.
The next step centres on modified antiplatelet therapy. Depending on the clinical picture, the protocol may involve an adjusted aspirin schedule or an alternative antiplatelet agent, with careful monitoring for tolerability. The complete regimen — including which option applies and the full structured approach — is available in the protocol.
DOI: 10.1002/ajh.27216
Figure 5 outlines our general treatment approach in ET, which starts with thrombosis risk stratification: very low (age ≤60 years, no thrombosis history, JAK2 wild-type), low (same as very low but JAK2 mutation present), intermediate (age >60 years, no thrombosis history, JAK2 wild-type), and high (thrombosis history present or age >60 years with JAK2 mutation).
In the presence of aspirin-resistant symptoms, it is reasonable to utilize a twice-daily rather than once-daily regimen of low-dose aspirin or alternative antiplatelet agents such as clopidogrel (75 mg/day) alone or in combination with aspirin, as long as patients are monitored closely for drug side effects.
View source ↗